Healthcare Equipment and Supplies
Company Overview of Amedica Corporation
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the United States, Europe, and South America. The company offers Valeo silicon nitride spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal surgery products for the treatment of deformity and degenerative spinal procedures. It also develops femoral heads for use in total hip replacements; and femoral condyle components for use in total knee replacements. The company markets and sells its products to surgeons and hospitals directly, as well as...
1885 West 2100 South
Salt Lake City, UT 84119
Founded in 1996
Key Executives for Amedica Corporation
Chairman of The Board, CEO, President & Principal Financial Officer
Total Annual Compensation: $409.6K
Chief Technology Officer
Total Annual Compensation: $257.4K
Compensation as of Fiscal Year 2015.
Amedica Corporation Key Developments
Amedica Corporation announced delayed 10-Q filing
Aug 16 17
On 08/16/2017, Amedica Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Amedica Corporation Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended of December 31, 2016
Jun 8 17
Amedica Corporation reported unaudited earnings results for the fourth quarter and full year ended of December 31, 2016. For the quarter, the company reported preliminary revenue of $3.7 million for the fourth quarter of 2016. Preliminary GAAP net loss was $0.16 per share, compared to net loss of $0.57 per share in the fourth quarter of 2015.
For the full year, the company reported preliminary revenue of $15.2 million for the full year. The company reported preliminary GAAP net loss of $1.19 per share, compared to a net loss of $5.50 per share in 2015.
Amedica Receives Non-Compliance Letter From The NASDAQ
May 26 17
Amedica Corporation announced that it has delayed the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 ("Form 10-Q"). Because the filing of the Company's Form 10-Q has been delayed beyond the 5-day extension period of Form 12b-25, on May 23, 2017, Amedica received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("NASDAQ") indicating that the Company is not in compliance with Listing Rule 5250(c)(1) because the Company has failed to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. Under the NASDAQ Listing Rules, because the Company is also delinquent on filing its Annual Report on Form 10-K for the period ended December 31, 2016, the Company has until June 19, 2017 to submit a plan to NASDAQ as to how it plans to regain compliance with NASDAQ's continued listing requirements. If the Company is still unable to file its Form 10-K and Form 10-Q by that time, then the Company intends to submit a compliance plan on or prior to that date. If NASDAQ accepts the Company's plan, NASDAQ can grant an exception of up to 180 calendar days from the filing's due date, or until September 27, 2017, to regain compliance. The Company may regain compliance at any time during this 180-day period upon filing with the SEC its Form 10-K and Form 10-Q, as well as all subsequent required periodic financial reports that are due within that period. If NASDAQ does not accept the Company's plan, Amedica will have the opportunity to appeal that decision to a NASDAQ Hearings Panel. The NASDAQ notification letter has no immediate effect on the listing of Amedica's common stock on the NASDAQ Capital Market.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 28, 2017